Morgan Stanley’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $65.4M | Buy |
936,560
+277,173
| +42% | +$20.3M | ﹤0.01% | 1966 |
|
|
2026
Q1 | $47.4M | Buy |
659,387
+92,966
| +16% | +$5.29M | ﹤0.01% | 2150 |
|
|
2025
Q4 | $23.9M | Sell |
566,421
-362,730
| -39% | -$20.3M | ﹤0.01% | 2763 |
|
|
2025
Q3 | $52.9M | Buy |
929,151
+857,012
| +1,188% | +$28.4M | ﹤0.01% | 1958 |
|
|
2025
Q2 | $1.86M | Buy |
72,139
+33,198
| +85% | +$373K | ﹤0.01% | 4745 |
|
|
2025
Q1 | $397K | Sell |
38,941
-14,548
| -27% | -$190K | ﹤0.01% | 5433 |
|
|
2024
Q4 | $746K | Buy |
53,489
+3,748
| +8% | +$66.1K | ﹤0.01% | 5236 |
|
|
2024
Q3 | $970K | Sell |
49,741
-48,434
| -49% | -$923K | ﹤0.01% | 5060 |
|
|
2024
Q2 | $1.83M | Buy |
98,175
+86,922
| +772% | +$1.83M | ﹤0.01% | 4623 |
|
|
2024
Q1 | $158K | Sell |
11,253
-25,264
| -69% | -$264K | ﹤0.01% | 5809 |
|
|
2023
Q4 | $309K | Sell |
36,517
-20,158
| -36% | -$153K | ﹤0.01% | 5535 |
|
|
2023
Q3 | $506K | Sell |
56,675
-48,233
| -46% | -$464K | ﹤0.01% | 5164 |
|
|
2023
Q2 | $905K | Sell |
104,908
-18,254
| -15% | -$195K | ﹤0.01% | 4891 |
|
|
2023
Q1 | $1.3M | Buy |
123,162
+13,613
| +12% | +$412K | ﹤0.01% | 4715 |
|
|
2022
Q4 | $3.71M | Sell |
109,549
-43,975
| -29% | -$2.13M | ﹤0.01% | 4002 |
|
|
2022
Q3 | $7.37M | Buy |
153,524
+840
| +0.6% | +$50K | ﹤0.01% | 3291 |
|
|
2022
Q2 | $8.7M | Buy |
152,684
+40,495
| +36% | +$2.56M | ﹤0.01% | 3207 |
|
|
2022
Q1 | $9.07M | Buy |
112,189
+12,165
| +12% | +$1.8M | ﹤0.01% | 3014 |
|
|
2021
Q4 | $20.3M | Buy |
100,024
+42,300
| +73% | +$9.18M | ﹤0.01% | 2125 |
|
|
2021
Q3 | $15.6M | Buy |
57,724
+25,923
| +82% | +$6.23M | ﹤0.01% | 2369 |
|
|
2021
Q2 | $8.19M | Sell |
31,801
-2,808
| -8% | -$777K | ﹤0.01% | 3226 |
|
|
2021
Q1 | $10.4M | Buy |
34,609
+3,697
| +12% | +$1.15M | ﹤0.01% | 2608 |
|
|
2020
Q4 | $7.88M | Buy |
30,912
+3,955
| +15% | +$1.02M | ﹤0.01% | 2767 |
|
|
2020
Q3 | $6.71M | Buy |
26,957
+1,284
| +5% | +$404K | ﹤0.01% | 2423 |
|
|
2020
Q2 | $8.92M | Sell |
25,673
-19,778
| -44% | -$6.17M | ﹤0.01% | 2069 |
|
|
2020
Q1 | $12.2M | Buy |
45,451
+6,945
| +18% | +$2.15M | ﹤0.01% | 1634 |
|
|
2019
Q4 | $12.5M | Buy |
38,506
+4,867
| +14% | +$1.41M | ﹤0.01% | 2157 |
|
|
2019
Q3 | $9.19M | Buy |
33,639
+3,265
| +11% | +$1.2M | ﹤0.01% | 2225 |
|
|
2019
Q2 | $16.2M | Sell |
30,374
-24,604
| -45% | -$12.3M | ﹤0.01% | 1668 |
|
|
2019
Q1 | $27.7M | Sell |
54,978
-38,283
| -41% | -$22.7M | 0.01% | 1206 |
|
|
2018
Q4 | $46M | Buy |
93,261
+7,278
| +8% | +$4.39M | 0.01% | 855 |
|
|
2018
Q3 | $78.6M | Buy |
85,983
+5,795
| +7% | +$4.95M | 0.02% | 719 |
|
|
2018
Q2 | $58.7M | Sell |
80,188
-4,978
| -6% | -$5.74M | 0.02% | 830 |
|
|
2018
Q1 | $136M | Buy |
85,166
+35,209
| +70% | +$45.4M | 0.04% | 458 |
|
|
2017
Q4 | $44.8M | Buy |
49,957
+3,087
| +7% | +$1.83M | 0.01% | 1021 |
|
|
2017
Q3 | $16.9M | Buy |
46,870
+2,713
| +6% | +$849K | 0.01% | 1735 |
|
|
2017
Q2 | $12.9M | Buy |
44,157
+4,623
| +12% | +$1.34M | ﹤0.01% | 1925 |
|
|
2017
Q1 | $13.9M | Sell |
39,534
-31,064
| -44% | -$6.98M | ﹤0.01% | 1894 |
|
|
2016
Q4 | $13M | Buy |
70,598
+30,899
| +78% | +$6.28M | ﹤0.01% | 1979 |
|
|
2016
Q3 | $10.2M | Buy |
39,699
+7,701
| +24% | +$1.98M | ﹤0.01% | 1988 |
|
|
2016
Q2 | $6.83M | Sell |
31,998
-1,916
| -6% | -$428K | ﹤0.01% | 2320 |
|
|
2016
Q1 | $7M | Buy |
33,914
+1,569
| +5% | +$301K | ﹤0.01% | 2190 |
|
|
2015
Q4 | $8.18M | Sell |
32,345
-1,488
| -4% | -$306K | ﹤0.01% | 2182 |
|
|
2015
Q3 | $5.56M | Sell |
33,833
-1,728
| -5% | -$306K | ﹤0.01% | 2558 |
|
|
2015
Q2 | $6.67M | Sell |
35,561
-1,535
| -4% | -$264K | ﹤0.01% | 2533 |
|
|
2015
Q1 | $6.12M | Buy |
37,096
+290
| +0.8% | +$59.6K | ﹤0.01% | 2560 |
|
|
2014
Q4 | $8.56M | Sell |
36,806
-356
| -1% | -$76.1K | ﹤0.01% | 2208 |
|
|
2014
Q3 | $6.73M | Sell |
37,162
-4,797
| -11% | -$918K | ﹤0.01% | 2374 |
|
|
2014
Q2 | $8.07M | Sell |
41,959
-1,861
| -4% | -$329K | ﹤0.01% | 2222 |
|
|
2014
Q1 | $7.97M | Sell |
43,820
-7,423
| -14% | -$1.47M | ﹤0.01% | 2143 |
|
|
2013
Q4 | $8.72M | Buy |
51,243
+13,491
| +36% | +$2.18M | ﹤0.01% | 2065 |
|
|
2013
Q3 | $5.92M | Buy |
37,752
+6,204
| +20% | +$1.15M | ﹤0.01% | 2251 |
|
|
2013
Q2 | $5.47M | Buy |
+31,548
| New | +$4.84M | ﹤0.01% | 2241 |
|
Other funds holding NKTR
TSC
BI
VPC
PM
Morgan Stanley's NKTR Position: Q2 2026 in Review
Morgan Stanley increased its Nektar Therapeutics (NKTR) stake by 42% in Q2 2026, buying an estimated $20.3M and bringing the position to 936,560 shares worth $65.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1966.
Morgan Stanley first reported a position in NKTR in Q2 2013 and has held it in 53 quarters since. The position peaked at $136M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.
- Morgan Stanley held 936,560 shares of Nektar Therapeutics worth $65.4M as of Q2 2026.
- Morgan Stanley bought 277,173 Nektar Therapeutics shares in Q2 2026, an estimated $20.3M.
- Nektar Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #1966 holding.
- Morgan Stanley first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Morgan Stanley's Nektar Therapeutics position peaked at $136M in Q1 2018.
- 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.